It Is an Isolated Incident That Is Unlikely It Will Repeat Again

• Dwelling house/
• Newsroom/
• Commentaries/
• Detail/
• Criteria for releasing COVID-19 patients from isolation

Groundwork

On 27 May 2020, WHO published updated interim guidance on the clinical direction of COVID-19,^i,2 and provided updated recommendations on the criteria for discharging patients from isolation. The updated criteria reflect recent findings that patients whose symptoms have resolved may still examination positive for the COVID-19 virus (SARS-CoV-2) by RT-PCR for many weeks. Despite this positive exam result, these patients are not probable to be infectious and therefore are unlikely to be able to transmit the virus to another person.

This scientific brief provides the rationale for the changes made to the clinical direction of COVID-nineteen guidance, based on recent scientific evidence.  WHO volition update these criteria as more than information becomes available. For more than information nearly clinical care of COVID-19 patients, see WHO'southward full guidance.¹

Previous recommendation

Initial recommendation (published on 12 January 2020)

WHO'south first technical parcel of guidance for the clinical management of the novel coronavirus, now known every bit COVID-19, was published in early on January 2020, shortly after a cluster of atypical pneumonia cases was first reported in Wuhan, People'due south Commonwealth of Mainland china,³ and included recommendations on when a patient with COVID-19 is no longer considered infectious.

The initial recommendation to confirm clearance of the virus, and thus allow belch from isolation, required a patient to be clinically recovered and to have 2 negative RT-PCR results on sequential samples taken at least 24 hours autonomously.^four This recommendation was based on our knowledge and feel with like coronaviruses, including those that cause SARS and MERS.⁵

Updated recommendation

New recommendation (published on 27 May 2020 as office of more comprehensive clinical intendance guidance1)

Within the Clinical Management of COVID-19 interim guidance published on 27 May 2020,¹ WHO updated the criteria for belch from isolation equally role of the clinical care pathway of a COVID-xix patient. These criteria apply to all COVID-nineteen cases regardless of isolation location or disease severity.

Criteria for discharging patients from isolation (i.e., discontinuing transmission-based precautions) without requiring retesting[1]:

• For symptomatic patients: 10 days afterward symptom onset, plus at to the lowest degree 3 additional days without symptoms (including without fever [2] and without respiratory symptoms)[3]
• For asymptomatic cases[4]: 10 days later positive test for SARS-CoV-2

For example, if a patient had symptoms for 2 days, then the patient could exist released from isolation afterwards 10 days + iii = 13 days from engagement of symptom onset; for a patient with symptoms for 14 days, the patient tin can be discharged (14 days + 3 days =) 17 days afterwards engagement of symptom onset; for a patient with symptoms for thirty days, the patient can exist discharged (30+3=) 33 days subsequently symptom onset).

*Countries may choose to proceed to use testing as part of the release criteria.  If so, the initial recommendation of 2 negative PCR tests at least 24 hours autonomously can exist used.

What is the reason for the modify?

In consultations with global skillful networks and Member States, WHO has received feedback that applying the initial recommendation of 2 negative RT-PCR tests at to the lowest degree 24 hours autonomously, in low-cal of limited laboratory supplies, equipment, and personnel in areas with intense transmission, has been extremely hard, especially exterior hospital settings.

With widespread community transmission, these initial criteria for SARS-CoV-2 posed several challenges:

• Long periods of isolation for individuals with prolonged viral RNA detection after resolution of symptoms, affecting individual well-being, social club ,and access to healthcare.^xiii
• Insufficient testing capacity to comply with initial belch criteria in many parts of the earth.
• Prolonged viral shedding around the limit of detection, having negative results followed past positive results, which unnecessarily challenges trust in the laboratory organisation.^23-28

These challenges and newly available information on the risk of viral transmission over the class of the COVID-xix illness provided the framework for updating WHO'south position on the timing of discharging recovered patients from isolation in and exterior wellness intendance facilities. WHO continuously reviews scientific literature on COVID-19 through its Scientific discipline Division and its COVID-19 technical teams. All aspects of clinical management of COVID-nineteen patients and laboratory testing strategies are discussed within WHO and with Fellow member States and WHO's global expert networks of public wellness professionals, clinicians, and academics around the world. These adept networks and the Strategic and Technical Informational Group for Infectious Hazards (STAG-IH)⁷ considered the challenges and reviewed the available data in the decision procedure to change the initial recommendation.

The updated criteria for discharge from isolation balances risks and benefits; even so, no criteria that can exist practically implemented are without risk.  At that place is a minimal residual hazard that transmission could occur with these not–test-based criteria.  There can be situations in which a minimal remainder gamble is unacceptable, for instance, in individuals at high risk of transmitting the virus to vulnerable groups or those in high-risk situations or environments. In these situations, and in patients who are symptomatic for prolonged periods of time, a laboratory-based approach can notwithstanding be useful.

WHO encourages the scientific community to compile additional prove to further better isolation discharge criteria and establish the conditions under which isolation can be abbreviated or where the possible risks of the current discharge criteria crave further adaptation. Ameliorate agreement of transmission risk among individuals with dissimilar clinical presentations or comorbidities and in dissimilar settings volition aid farther refinement of these criteria. For situations that might all the same require a laboratory-based approach, we encourage the farther optimization of such a laboratory algorithm. WHO encourages countries to go along testing patients, if they have the capacity to do so, for systematic data collection that will heighten understanding and better guide decisions about infection prevention and command measures, especially amongst patients with prolonged illness or those who are immunocompromised.

Current understanding of transmission risk

Infection with the virus causing COVID-nineteen (SARS-CoV-ii) is confirmed by the presence of viral RNA detected past molecular testing, usually RT-PCR.  Detection of viral RNA does not necessarily mean that a person is infectious and able to transmit the virus to another person. Factors that determine transmission risk include whether a virus is notwithstanding replication-competent, whether the patient has symptoms, such as a cough, which can spread infectious aerosol, and the beliefs and environmental factors associated with the infected private. Normally 5-x days afterward infection with SARS-CoV-two, the infected individual starts to gradually produce neutralizing antibodies. Binding of these neutralizing antibodies to the virus is expected to reduce the risk of virus transmission.^x,11,29,35

SARS-CoV-2 RNA has been detected in patients 1-3 days before symptom onset, and viral load in the upper respiratory tract peaks within the first week of infection, followed by a gradual decline over fourth dimension.^{x,12,15,19,21,22,36-39} In the feces and lower respiratory tract, this viral load seems to acme in the second calendar week of illness.¹⁹ Viral RNA has been detected in upper respiratory tract (URT) and lower respiratory tract (LRT) and feces, regardless of severity of affliction.^xix There seems to be a trend in longer detection of viral RNA in more than severely ill patients.^{x,14,xv,18,xix,41-43}Studies of viral RNA detection in immunocompromised patients are limited, but ane study suggested prolonged detection of viral RNA in renal transplant patients.³³ Some studies analyzed the risk of transmission related to symptom of onset, and the estimated risk of transmission was highest at or effectually the time of symptom onset and in the first 5 days of illness.^thirteen,15

The ability of the virus to replicate in cultured cells serves equally a surrogate marker of infectivity but requires special laboratory capabilities and may non be as sensitive as PCR.^10,20 Animate being models can aid understanding of manual risk. In a study by Sia, et al., hamsters infected with SARS-CoV-2 were housed with healthy hamsters on either day i or solar day half dozen after infection. Transmission to healthy hamsters occurred in the day i group, but not in those exposed six days later on inoculation. In this model, the timing of transmission correlated with the detection of virus using prison cell civilization, but not with detection of viral RNA in donor nasal washes.³¹

Studies using viral culture of patient samples to assess the presence of infectious SARS-CoV-two are limited.^{8-x,21,29,xxx,34}Feasible virus has been isolated from an asymptomatic example.⁹ A study of ix  COVID-19 patients with mild to moderate disease plant no SARS-CoV-2 virus able to exist cultured from respiratory samples after solar day 8 of symptom onset.^ten Three studies of patients with undisclosed or variable caste of illness showed an inability to civilization virus after days 7-9 of symptom onset.^8,29,xxx  Patients who were RT-PCR positive on retesting later an initial negative RT-PCR on discharge from isolation were also studied, and none of these patients yielded positive viral cultures.²⁹ 1 possible outlier is a case report of a patient with mild COVID-nineteen who remained PCR-positive for 63 days later on symptom onset. In this patient, viral cultures were positive from upper respiratory tract specimens only on the day of symptom onset, but were civilisation-positive from sputum samples until twenty-four hours eighteen.²² It is unclear whether this posed a transmission run a risk as the patient had no respiratory symptoms. In a hospital-based written report of 129 patients severely or critically ill with  COVID-19, 23 patients yielded at least one positive viral culture. This written report included thirty patients who were immunocompromised. The median duration of viral shedding as measured by civilization was 8 days postal service onset, the interquartile range was 5-11, and the range was 0-20 days.^eleven The probability of detecting virus in culture dropped beneath 5% after 15.2 days after of symptoms. In this study, patients testing positive past viral culture were still experiencing symptoms at the time of sample collection.¹¹ This and other studies have described the correlation between reduced infectivity with the decrease in viral loads^10,11,29,34 and a rise in neutralizing antibodies.^x,11,29 Although viral RNA tin can be detected by PCR even subsequently the resolution of symptoms, the corporeality of detected viral RNA is substantially reduced over time and generally below the threshold where replication competent virus can be isolated. Therefore, the combination of time after onset of symptoms and the clearance of symptoms seems to be a by and large safe approach based on current data.

Decision

Based on bear witness showing the rarity of virus that can be cultured in respiratory samples later on ix days subsequently symptom onset, peculiarly in patients with mild disease, usually accompanied by rising levels of neutralizing antibodies and a resolution of symptoms, it appears safety to release patients from isolation based on clinical criteria that require a minimum time in isolation of xiii days, rather than strictly on repeated PCR results. Information technology is of import to note that the clinical criteria require that patients' symptoms have been resolved for at to the lowest degree three days earlier release from isolation, with a minimum fourth dimension in isolation of xiii days since symptom onset.

These modifications to the criteria for discharge from isolation (in a health facility or elsewhere) remainder the understanding of infectious risk and the practicality of requiring repeated negative PCR testing, especially in settings of intense transmission or express testing supplies. Although the risk of manual afterwards symptom resolution is likely to be minimal based on what is currently known, it cannot be completely ruled out. However, there is no nix-hazard approach, and strict reliance on PCR confirmation of viral RNA clearance creates other risks (eastward.g. straining resources and limiting access to wellness care for new patients with acute disease). In patients with severe disease who are symptomatic for prolonged periods of time, a laboratory-based approach might also aid decision-making on the demand for prolonged isolation. Such a laboratory-based approach can include measuring viral load and neutralizing antibody (or proven equivalent antibody) levels.^10,xi,29 More than research is needed to farther validate such an approach.

WHO will update these criteria as more information becomes available. For more than data well-nigh clinical care of COVID-19 patients, meet WHO's full guidance.¹

[1] Countries can choose to keep to apply a laboratory testing algorithm equally function of the release criteria in (a subset of) infected individuals if their risk assessment gives reason to practice so.

[2] Without the utilise of any antipyretics.

[3] Some patients may feel symptoms (such every bit post viral cough) beyond the period of infectivity. Further research is needed. For more information about clinical care of COVID-nineteen patients, see our Clinical Direction Guidance.^ane

[iv] An asymptomatic case is an individual who has a laboratory confirmed positive test and who has no symptoms during the complete course of infection.

References

1. World Wellness Arrangement. Clinical direction of COVID-19 (Interim Guidance) https://www.who.int/publications-detail/clinical-management-of-covid-19, published 27 May 2020.
2. Earth Wellness System. Coronavirus affliction (COVID-19) Situation Report – 129. 28 May 2020. Bachelor at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200528-covid-19-sitrep-129.pdf?sfvrsn=5b154880_2
3. ProMED International Guild for Communicable diseases. 30 December 2019. (https://promedmail.org/promed-postal service/?id=6864153%xx#COVID19 )
4. Globe Health Organization. Laboratory testing of human suspected cases of novel coronavirus (nCOV) infection (Interim Guidance) (https://apps.who.int/iris/bitstream/handle/10665/330374/WHO-2019-nCoV-laboratory-2020.one-eng.pdf 10 January 2020)
5. World Health Organisation. Technical guidance laboratory Middle East Respiratory syndrome coronavirus (MERS-CoV) (https://www.who.int/csr/disease/coronavirus_infections/technical-guidance-laboratory/en/)
6. World Wellness Organization. Global surveillance for COVID-19 acquired by human infection with COVID-19 virus. (Interim Guidance) (https://www.who.int/publications/i/detail/global-surveillance-for-covid-19-caused-by-human-infection-with-covid-xix-virus-interim-guidance, 20 April 2020)
7. World Health System. Strategic and Technical Advisory Grouping for Infectious Hazards (STAG IH)  (https://world wide web.who.int/emergencies/diseases/strategic-and-technical-informational-group-for-infectious-hazards/en/)
8. Bullard J, Dusk Thousand, Funk D, et al. Predicting infectious SARS-CoV-ii from diagnostic samples, Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa638.
9. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV ii infections and transmission in a skilled nursing facility. North Engl J Med. 2020; 382: 2081-90.
10. Wolfel R, Corman VM, Guggemos Due west, et al. Virological assessment of hospitalized patients with COVID-19. Nature. 2020; 581: 465-69.
11. Personal communication with van Kampen JJA first author of preprint of: Van Kampen JJA, Van de Vijner DAMC, Fraaij PLA, et al. Shedding of infectious virus in hospitalized patients with coronavirus illness 2019 (COVID-xix): duration and primal determinants. (Preprint) Medrxiv. 2020 doi: 10.1101/2020.06.08.20125310.
12. To KK, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort report. Lancet Infect Dis. 2020; xx(5): p. 565-74.
13. Cheng HY, Jian South, Liu D, et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Unlike Exposure Periods Earlier and After Symptom Onset. JAMA Intern Med. 2020; e202020.  doi: 10.1001/jamainternmed.2020.2020.
14. Zhou R, Li F, Chen F, et al. Viral dynamics in asymptomatic patients with COVID-19. Int J Infect Dis. 2020 doi: 10.1016/j.ijid.2020.05.030.
15. He 10, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-nineteen. Nat Med. 2020; 26(v): p.672-5.
16. Lu Y, Li Y, Deng W, et al. Symptomatic infection is associated with prolonged elapsing of viral shedding in mild coronavirus disease 2019: A retrospective study of 110 children in Wuhan. Pediatr Infect Dis J. 2020; 39(7): e95-9. doi: x.1097/INF.0000000000002729.
17. Munster VJ, Feldmann F, Williamson BN, et al. Respiratory affliction in rhesus macaques inoculated with SARS-CoV-2. Nature. 2020 doi: 10.1038/s41586-020-2324-7.
18. Widders A, Broom A, Broom J. SARS-CoV-2: The viral shedding vs infectivity dilemma. Infection Dis Wellness. 2020 doi: 10.1016/j.idh.2020.05.002.
19. Weiss A, Jellingsoe Yard, Sommer MOA. Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systemic review. (Preprint) Medrxiv. 2020 doi: 10.1101/2020.05.21.20108605.
20. World Health Organization. Laboratory biosafety guidance related to coronavirus disease (COVID-19) (https://www.who.int/publications/i/item/laboratory-biosafety-guidance-related-to-coronavirus-disease-(covid-19 , 13 May 2020)
21. The COVID-19 Investigation Team. Clinical and virologic characteristics of the start 12 patients with coronavirus illness 2019 (COVID-19) in the United States. Nat Med; 2020 doi: 10.1038/s41591-020-0877-5.
22. Liu WD, Chang SY, Wang JT, et al. Prolonged virus shedding fifty-fifty after seroconversion in a patient with COVID-19. J Infect. 2020 doi: 10.1016/j.jinf.2020.03.063.
23. Yuan J, Kou S, Liang Y, et al. PCR Assays Turned Positive in 25 Discharged COVID-nineteen Patients. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa398.
    
24. Tang X, Zhao South, He D, et al. Positive RT-PCR tests amongst discharged COVID-19 patients in Shenzhen, China. Infect Control Hosp Epidemiol. 2020 doi: ten.1017/water ice.2020.134.
    
25. Qu YM, Kang EM, Cong HY. Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-nineteen. Travel Med Infect Dis. 2020; 34: p101619. doi: x.1016/j.tmaid.2020.101619.
    
26. Li Y, Hu Y, Yu Y, et al. Positive result of Sars-Cov-2 in faeces and sputum from discharged patient with COVID-19 in Yiwu, China. J Med Virol. 2020 doi: 10.1002/jmv.25905.
27. Xiao AT, Tong YX, Zhang South. Simulated-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence. J Med Virol. 2020 doi: 10.1002/jmv.25855.
28. Xing Y, Mo P, Xiao Y et al. Postal service-belch surveillance and positive virus detection in two medical staff recovered from coronavirus affliction 2019 (COVID-19), Mainland china, January to February 2020. Euro Surveill, 2020; 25(10): 2000191. doi: 10.2807/1560-7917.ES.2020.25.10.2000191.
29. Unpublished data, manuscript in training, personal communication Malik Peiris, Hong Kong University.
30. Centers for Disease Control and Prevention, Coronavirus Illness 2019 (COVID-nineteen). Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-nineteen.  Website, accessed on 12 June 2020. https://www.cdc.gov/coronavirus/2019-ncov/community/strategy-discontinue-isolation.html
31. Sia SF, Yan LM, Chin AWH et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020 doi: ten.1038/s41586-020-2342-5.
32.  Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-ii in Dissimilar Types of Clinical Specimens. JAMA. 2020; 323(eighteen): 1843-4. doi:ten.1001/jama.2020.3786.
33.  Zhu L, Gong N, Liu B, et al. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China. Eur Urol. 2020; 77(vi):748-54.
34. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load every bit determined by prison cell civilisation equally a direction tool for discharge of SARS-CoV-2 from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020 doi: 10.1007/s10096-020-03913-ix.
35. Atkinson B, Petersen E. SARS-CoV-2 shedding and infectivity. Lancet. 2020; 395(10233): p.1339-xl.
36. Zou Fifty, Ruan F, Huang 1000, et al. SARS-CoV-two Viral Load in Upper Respiratory Specimens of Infected Patients. Due north Engl J Med. 2020; 382(12): p.1177-9.
37. Young Exist, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020;323(fifteen):1488–1494. doi:10.1001/jama.2020.3204.
38. Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a example series. Lancet Infect Dis. 2020; twenty(vi): p. 697-706. doi: ten.1016/S1473-3099(20)30200-0.
39.  Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-ii in clinical samples. Lancet Infect Dis. 2020; 20(4): p. 411-2. doi: ten.1016/S1473-3099(twenty)30113-4.
40. Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020; 133(9): p. 1039-43. doi: 10.1097/CM9.0000000000000774.
41. Hu Z, Son C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened amongst shut contacts in Nanjing, Mainland china. Sci Communist china Life Sci. 2020; 63(v): p. 706-11. doi: 10.1007/s11427-020-1661-4.
42. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis. 2020 doi: ten.1093/cid/ciaa351.
43. Qi L, Yang Y, Jiang D, et al. Factors associated with duration of viral shedding in adults with COVID-19 outside of Wuhan, Prc: A retrospective cohort written report. Int J Infect Dis. 2020 doi: 10.1016/j.ijid.2020.05.045.

Want to read more?

Criteria for releasing COVID-xix patients from isolation

tuckerentaid.blogspot.com

Source: https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation

Share this post